

Advanced Glycation End Products Market Size at Highest Revenue US\$ 2,130.1 Million with Growth Rate at 6.3% CAGR by 2027


SEATTLE , WASHINGTON, UNITED STATES, January 24, 2022

/EINPresswire.com/ -- Publisher's

[Advanced Glycation End Products](#)

[market](#)

research report provides the newest industry data and industry future trends, allowing you to identify the products and end users driving Revenue growth and profitability. The industry report lists the leading competitors and provides the insights strategic industry Analysis of the key factors influencing the market. The report includes the forecasts, Analysis and discussion of important industry trends, market size, market share estimates and profiles of the leading industry Players.



Advanced Glycation End Products

Advanced Glycation End Products Market, by Type (Non-fluorescent AGEs (Carboxymethyl-lysine (CML), Carboxyethyl-lysine (CEL), and Pyrraline) and Fluorescent AGEs (Pentosidine and Methylglyoxal-lysine dimer (MOLD))), by Application (Diabetic Complications, Cancer, Bone Diseases, Neurodegenerative Diseases, and Others), by End User (Hospitals, Specialty Clinics, and Homecare Settings), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US\$ 2,130.1 Million in 2021 and is expected to exhibit a CAGR of 6.3% over the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.

Advanced Glycation End Products Market, by Type (Non-fluorescent AGEs (Carboxymethyl-lysine (CML), Carboxyethyl-lysine (CEL), and Pyrraline) and Fluorescent AGEs (Pentosidine and Methylglyoxal-lysine dimer (MOLD))), by Application (Diabetic Complications, Cancer, Bone Diseases, Neurodegenerative Diseases, and Others), by End User (Hospitals, Specialty Clinics, and Homecare Settings), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US\$ 2,130.1 Million in 2021 and is expected to exhibit a CAGR of 6.3% over the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.

For more information, contact Coherent Market Insights at

<https://www.coherentmarketinsights.com/insight/request-sample/4350>

Coherent Market Insights:

Advanced glycation end products are proteins or lipids that become glycated after exposure to sugars. Irreversible nonenzymatic reactions between reducing sugars, such as glucose, and amino groups in proteins, lipids, and nucleic acids helps to form advanced glycation end products. Recent studies have found link between advanced glycation end products and liver cancer. In May 2021, researchers at the International Agency for Research on Cancer in Lyon, France, high AGEs intake increases risk for gallbladder cancer.

□□□□□□□□□□ □□□□□□□□:

Major players operating in the global advanced glycation end products market include, Allergan Plc, Beiersdorf AG, Estée Lauder Companies, L'Oréal S.A, NuFACE, Ostium Cosmetics, PhotoMedex, Inc., Rodan & Fields, LLC, and Shiseido Company.

□□□ □□□□□□ □□□□□□□□:

High prevalence of diabetes is expected to propel growth of the global advanced glycation end-products market over the forecast period. For instance, according to the study, 'Global Prevalence of Type 2 Diabetes over the Next Ten Years (2018-2028)', published by the American Diabetes Association, 500 million people worldwide suffered from type 2 diabetes in 2018.

□□ □□□ □□□□□□□□ □□□ □□□□□□□□ □□□□ @
<https://www.coherentmarketinsights.com/insight/request-pdf/4350>

□□□□□-□□ □□□□□□ □□□□□□□□

Globally, as of 6:04pm CET, 12 January 2022, there have been 312,173,462 confirmed cases of COVID-19, including 5,501,000 deaths, reported to WHO. As of 11 January 2022, a total of 9,194,549,698 vaccine doses have been administered. In November 2020, vTv Therapeutics Inc. reported baseline characteristics for the enrolled subjects in the ongoing Elevage clinical study of azeliragon as a potential treatment for mild Alzheimer's disease in people with type 2 diabetes. Approximately 35% of patients with Alzheimer's disease have type 2 diabetes, with associated increased advanced glycation end products and increased expression of the Receptor for Advanced Glycation End products, the target for azeliragon.

□□□ □□□□□□□□□□

Major players operating in the global advanced glycation end products market are focused on adopting partnership strategies to expand their product portfolio. For instance, in June 2021, vTv Therapeutics Inc. entered into a licensing agreement with Cantex Pharmaceuticals, Inc. under which Cantex obtained exclusive worldwide rights to develop and commercialize azeliragon, vTv's novel antagonist of RAGE (the receptor for advanced glycation endproducts).

0000 0000 0000 0000 0000 0000 0000

0000000000 0000 00000000 00000000 00 00000000 0000 0000000000000 @
<https://www.coherentmarketinsights.com/promo/buynow/4350>

About Us:

Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

Mr. Shah

Coherent Market Insights Pvt. Ltd.

+1 206-701-6702

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

[Other](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/561372456>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 IPD Group, Inc. All Right Reserved.